Clinical evaluation of the use of inhalation of 6% N-acetylcysteine in 3% NaCL solution (Flu-Acyl Broncho) in the treatment of children with acute bronchitis
DOI:
https://doi.org/10.15574/SP.2022.127.126Keywords:
acute bronchitis, mucolytics, children, inhalationAbstract
Purpose - to propose an optimization of treatment of acute bronchitis in children by introducing inhalation of FLU-ACIL broncho before therapy.
Materials and methods. An open, prospective, multicenter, non-interventional, comparative (with active control) study with two therapeutic groups was conducted. The experience of therapy of 45 children with moderate acute bronchitis aged 2-12 years old was summarized. The main group included 30 children who received inhalation of Flu-Acyl Broncho in the complex treatment: 5 ml 2 times a day 3-4 hours before bedtime for 7-10 days; the comparison group included 15 children who received oral acetylcysteine/ambroxol for 7-12 days. If it is necessary, antipyretic therapy with ibuprofen or paracetamol was used. The period from the onset of the disease to participation in the study was about 2-4 days. The study did not include children with concomitant acute middle ear diseases, acute sinusitis, acute allergic diseases and children with symptoms of obstruction.
The results of examination and treatment of patients were analyzed using the software package «Statistica 6.0 for Windows».
Results and conclusions. Comprehensive treatment of acute bronchitis in children with the administration of the inhalation Flu-Acyl Broncho, sterile solution for nebulizer and instillation, has a positive clinical effect, leads to faster relief (p<0.01) and disappearance (p<0.05) of cough compared to oral mucolytics. The additional anti-inflammatory and mucolytic effect of the inhalation route of administration of Flu-Acyl Broncho on the nasopharyngeal mucosa improves the results of treatment of children with concomitant acute respiratory pathology of the upper respiratory tract. This is manifested in faster, compared to oral mucolytics, elimination of rhinitis (p<0.001) and sore throat (p<0.05).
All studies were performed in accordance with the ethical principles adopted by the Declaration of Helsinki and Good Clinical Practice (GCP) for medical research conducted on human subjects. Approval was obtained from the ethics committee of the Children’s Clinical Hospital No. 5 of Sviatoshynskyi district of Kyiv.
No conflict of interests was declared by the authors.
References
Brodier EA, Raithatha M, Kannan S, Karunasekara N. (2020). Use of nebulised N-acetylcysteine as a life-saving mucolytic in intensive care: A case report. J Intensive Care Soc. 21 (4): 296-298. https://doi.org/10.1177/1751143719870089; PMid:34093730 PMCid:PMC8142091
Clark TW, Medina MJ, Batham S, Curran MD, Parmar S, Nicholson KG. (2014). Adults hospitalised with acute respiratory illness rarely have detectable bacteria in the absence of COPD or pneumonia; viral infection predominates in a large prospective UK sample. J Infect. 69 (5): 507-515. https://doi.org/10.1016/j.jinf.2014.07.023; PMid:25108123 PMCid:PMC7112687
European Medicines Agency (EMA). (2015). Revised assessment report - procedure under article 31 of directive 2001/83/EC resulting from pharmacovigilance data. Ambroxol and bromhexine containing medicinal products. URL: https://www.ema.europa.eu/documents/referral/ambroxol-bromhexine-article-31-referral-prac-assessment-report_en.pdf.EMA/PRAC/800767/2015. Published September 10, 2015.
Hagiwara SI, Ishii Y, Kitamura S. (2000). Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med. 162: 225-231. https://doi.org/10.1164/ajrccm.162.1.9903129; PMid:10903246
Hongbo L, Wenxiao W, Xingjuan G. (2020). Comparison of the efficacy of ambroxol hydrochloride and N-acetylcysteine in the treatment of children with bronchopneumonia and their influence on prognosis. Exp Ther Med. 20 (6): 130. https://doi.org/10.3892/etm.2020.9260; PMid:33082862 PMCid:PMC7557708
Kanie S, Yokohira M, Yamakawa K, Nakano-Narusawa Y, Yoshida S, Hashimoto N, Imaida K. (2017). Suppressive effects of the expectorant drug ambroxol hydrochloride on quartz-induced lung inflammation in F344 rats.J Toxicol Pathol. 30 (2): 153-159. https://doi.org/10.1293/tox.2016-0050; PMid:28458453 PMCid:PMC5406594
Kochuieva MM, Hrek II, Rohozhyn AV, Kochuiev HI. (2021). Zastosuvannia inhaliatsiinykh zasobiv dlia znyzhennia chastoty zahostren khronichnoho bronkhitu. Ukr. Med. Chasopys. 4 (144); VII/VIII: 2-6.
Kryvopustov SP. (2017). Kombinovana mukoaktyvna terapiia zakhvoriuvan dykhalnykh shliakhiv u ditei, shcho suprovodzhuiutsia utvorenniam viazkoho sekretu. Zdorove rebenka. 12 (2): 33-35.
Liu H, Wang W, Gao X. (2020). Comparison of the efficacy of ambroxol hydrochloride and N-acetylcysteine in the treatment of children with bronchopneumonia and their influence on prognosis. Exp Ther Med. 20 (6): 130. https://doi.org/10.3892/etm.2020.9260; PMid:33082862 PMCid:PMC7557708
Marushko Iu, Gischak Т, Lysovetz О, Muka M, Marushko E. (2015). Antitussive and expectorant treatment with acute respiratory diseases in children Sovremennaya pediatriya. 6 (70): 51-55. https://doi.org/10.15574/SP.2015.70.51
Marushko YuV, Hyshchak TV, Yesipova SI, Dolynna OV, Iovitsa TV. (2022). Efficacy and safety of inhalation 6% N-acetylcysteine in 3% NaCl solution in clinical practice (literature review). Modern Pediatrics. Ukraine. 6 (126): 120-126. https://doi.org/10.15574/SP.2022.126.120
Marushko YuV, Hyshchak TV. (2013). Dyferentsiiovani pidkhody do terapii kashliu u ditei, yaki chasto khvoriiut na hostri respiratorni zakhvoriuvannia. Zdorov'ia Ukrainy. 23 (324): 57-58.
Marushko YuV, Hyshchak TV. (2016). Utvorennia bioplivok pry respiratornii patolohii. Vplyv ambroksolu na bioplivky dykhalnykh shliakhiv (ohliad literatury). Zdorove rebenka. 2: 88-94. https://doi.org/10.22141/2224-0551.2.70.2016.73816
Marushko YuV, Hyshchak TV. (2020). Dosvid vykorystannia kombinovanoho vidkharkuvalnoho preparatu pry pozalikarnianii pnevmonii u ditei doshkilnoho viku. Simeina Medytsyna. 4 (90): 82-86.
Marushko YuV, Moskovenko ED, Bryuzgina TS. (2016). Effiency of primrose syrup phytopreparation in the treatment of acute bronchitis in children. Sovremennaya pediatriya. 8: 79-83.
Masoompour SM, Anushiravani A, Norouz AT. (2015). Evaluation of the Effect of Nebulized N-Acetylcysteine on Respiratory Secretions in Mechanically Ventilated Patients: Randomized Clinical Trial. Iran J Med Sci. 40(4): 309-315.
Masoompour SM, Anushiravani A, Tafaroj Norouz A. (2015). Evaluation of the Effect of Nebulized N-Acetylcysteine on Respiratory Secretions in Mechanically Ventilated Patients: Randomized Clinical Trial. Iran J Med Sci. 40 (4): 309-315.
McCarthy SD, González HE, Higgins BD. (2020). Future Trends in Nebulized Therapies for Pulmonary Disease. Journal of Personalized Medicine. 10 (2): 37. https://doi.org/10.3390/jpm10020037; PMid:32397615 PMCid:PMC7354528
McGinn KA, Weigartz K, Lintner A, Scalese MJ, Kahn SA. (2019). Nebulized Heparin With N-Acetylcysteine and Albuterol Reduces Duration of Mechanical Ventilation in Patients With Inhalation Injury. J Pharm Pract. 32 (2): 163-166. https://doi.org/10.1177/0897190017747143; PMid:29233052
MOZ Ukrainy. (2022). Nastanova 00620. Pnevmoniia u ditei. URL: https://www.dec.gov.ua/wp-content/uploads/2022/08/2022_1380_kn_pnevmoniyi_u_ditej.pdf.
Naz F, Raza AB, Ijaz I, Kazi MY. (2014). Effectiveness of nebulized N-acetylcysteine solution in children with acute bronchiolitis. Journal of College of Physicians and Surgeons Pakistan. 24 (6): 408-411.
Otu A, Langridge P, Denning DW. (2018). Nebulised N-Acetylcysteine for Unresponsive Bronchial Obstruction in Allergic Brochopulmonary Aspergillosis: A Case Series and Review of the Literature. J. Fungi. 4: 117. https://doi.org/10.3390/jof4040117; PMid:30326585 PMCid:PMC6308940
Petrini O. (2019). Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive? Clin Med Insights Ear Nose Throat. 9; 12: 1179550618821930. https://doi.org/10.1177/1179550618821930; PMid:30670922 PMCid:PMC6328955
Pogrebniak OO. (2016). Hipertonichnyi rozchyn natriiu khlorydu - prostyi ta efektyvnyi zasib u likuvanni osnovnykh zakhvoriuvan orhaniv dykhannia. Liky Ukrainy. 5-6 (201-202): 10-16. https://doi.org/10.37987/1997-9894.2016.5-6(201-2).204726
Šalamon Š, Kramar B, Marolt TP et al. (2019). Medical and Dietary Uses of N-Acetylcysteine. Antioxidants (Basel, Switzerland). 8 (5): 111. https://doi.org/10.3390/antiox8050111; PMid:31035402 PMCid:PMC6562654
Scaglione F, Petrini O. (2019). Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive? Clin Med Insights Ear Nose Throat. 9; 12: 1179550618821930. https://doi.org/10.1177/1179550618821930; PMid:30670922 PMCid:PMC6328955
Schwalfenberg GK. (2021, Jun 9). N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks). J Nutr Metab. 2021: 9949453. https://doi.org/10.1155/2021/9949453; PMid:34221501 PMCid:PMC8211525
Zhang Y, Fu Y, Yu J, Ai Q, Li J, Peng N, Song S, He Y, Wang Z. (2015). Synergy of ambroxol with vancomycin in elimination of cathe ter-related Staphylococcus epidermidis biofilm in vitro and in vivo. J. Infect Chemother. 21 (11): 808-815. https://doi.org/10.1016/j.jiac.2015.08.017; PMid:26423688
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
